1
|
Zhou H, He J, Liu R, Cheng J, Yuan Y, Mao W, Zhou J, He H, Liu Q, Tan W, Shuai C, Deng Y. Microenvironment-responsive metal-phenolic network release platform with ROS scavenging, anti-pyroptosis, and ECM regeneration for intervertebral disc degeneration. Bioact Mater 2024; 37:51-71. [PMID: 38515609 PMCID: PMC10954684 DOI: 10.1016/j.bioactmat.2024.02.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 02/13/2024] [Accepted: 02/29/2024] [Indexed: 03/23/2024] Open
Abstract
Intervertebral disc degeneration (IVDD) can be caused by aging, injury, and genetic factors. The pathological changes associated with IVDD include the excessive accumulation of reactive oxygen species (ROS), cellular pyroptosis, and extracellular matrix (ECM) degradation. There are currently no approved specific molecular therapies for IVDD. In this study, we developed a multifunctional and microenvironment-responsive metal-phenolic network release platform, termed TMP@Alg-PBA/PVA, which could treat (IL-1β)-induced IVDD. The metal-phenolic network (TA-Mn-PVP, TMP) released from this platform targeted mitochondria to efficiently scavenge ROS and reduce ECM degradation. Pyroptosis was suppressed through the inhibition of the IL-17/ERK signaling pathway. These findings demonstrate the versatility of the platform. And in a rat model of IVDD, TMP@Alg-PBA/PVA exhibited excellent therapeutic effects by reducing the progression of the disease. TMP@Alg-PBA/PVA, therefore, presents clinical potential for the treatment of IVDD.
Collapse
Affiliation(s)
- Hao Zhou
- Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
- Department of Joint Surgery and Sports Medicine, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421002, China
| | - Jinpeng He
- Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
| | - Renfeng Liu
- Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
| | - Jun Cheng
- Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
| | - Yuhao Yuan
- Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China
| | - Wanpu Mao
- Department of Joint Surgery and Sports Medicine, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421002, China
| | - Jun Zhou
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China
| | - Honghui He
- Department of Joint Surgery and Sports Medicine, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421002, China
| | - Qianqi Liu
- Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
| | - Wei Tan
- Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
| | - Cijun Shuai
- State Key Laboratory of High Performance Complex Manufacturing, College of Mechanical and Electrical Engineering, Central South University, Changsha, 410083, China
| | - Youwen Deng
- Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
| |
Collapse
|
2
|
Zhang A, Pan Y, Wang H, Ding R, Zou T, Guo D, Shen Y, Ji P, Huang W, Wen Q, Wang Q, Hu H, Wu J, Xiang M, Ye B. Excessive processing and acetylation of OPA1 aggravate age-related hearing loss via the dysregulation of mitochondrial dynamics. Aging Cell 2024; 23:e14091. [PMID: 38267829 PMCID: PMC11019136 DOI: 10.1111/acel.14091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 01/09/2024] [Accepted: 01/10/2024] [Indexed: 01/26/2024] Open
Abstract
The pathogenesis of age-related hearing loss (ARHL) remains unclear. OPA1 is the sole fusion protein currently known to be situated in the inner mitochondrial membrane, which is pivotal for maintaining normal mitochondrial function. While it has already been demonstrated that mutations in OPA1 may lead to hereditary deafness, its involvement in the occurrence and development of ARHL has not been previously explored. In our study, we constructed D-gal-induced senescent HEI-OC1 cells and the cochlea of C57BL/6J mice with a mutated SUMOylation site of SIRT3 using CRISPR/Cas9 technology. We found enhanced L-OPA1 processing mediated by activated OMA1, and increased OPA1 acetylation resulting from reductions in SIRT3 levels in senescent HEI-OC1 cells. Consequently, the fusion function of OPA1 was inhibited, leading to mitochondrial fission and pyroptosis in hair cells, ultimately exacerbating the aging process of hair cells. Our results suggest that the dysregulation of mitochondrial dynamics in cochlear hair cells in aged mice can be ameliorated by activating the SIRT3/OPA1 signaling. This has the potential to alleviate the senescence of cochlear hair cells and reduce hearing loss in mice. Our study highlights the significant roles played by the quantities of long and short chains and the acetylation activity of OPA1 in the occurrence and development of ARHL. This finding offers new perspectives and potential targets for the prevention and treatment of ARHL.
Collapse
Affiliation(s)
- Andi Zhang
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Yi Pan
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Hao Wang
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Rui Ding
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Tianyuan Zou
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Dongye Guo
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Yilin Shen
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Peilin Ji
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Weiyi Huang
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Qing Wen
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Quan Wang
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Haixia Hu
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Jichang Wu
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Mingliang Xiang
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
- Department of Audiology & Speech‐Language Pathology, College of Health Science and TechnologyShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Bin Ye
- Department of Otolaryngology & Head and Neck Surgery, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Translational Medicine on Ear and Nose DiseasesShanghaiChina
- Ear InstituteShanghai Jiao Tong University School of MedicineShanghaiChina
- Department of Audiology & Speech‐Language Pathology, College of Health Science and TechnologyShanghai Jiao Tong University School of MedicineShanghaiChina
| |
Collapse
|
3
|
Chen X, Zhang P, Zhang Y, Wei M, Tian T, Zhu D, Guan Y, Wei W, Ma Y. The research progression of direct NLRP3 inhibitors to treat inflammatory disorders. Cell Immunol 2024; 397-398:104810. [PMID: 38324950 DOI: 10.1016/j.cellimm.2024.104810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Revised: 01/08/2024] [Accepted: 01/15/2024] [Indexed: 02/09/2024]
Abstract
The NLRP3 inflammasome represents a cytoplasmic multiprotein complex with the capability to recognize a wide range of pathogen-derived, environmental, and endogenous stress-related factors. Dysregulated activation of the NLRP3 inflammasome has been implicated in the development of various inflammasome-associated disorders, highlighting its significance as a pivotal target for the treatment of inflammatory diseases. Nonetheless, despite its clinical importance, there is currently a lack of specific drugs available for directly targeting the NLRP3 inflammasome. Several strategies have been explored to target different facets of the NLRP3 inflammasome, with interventions aimed at directly inhibiting NLRP3 demonstrating the most promising efficacy and safety profiles. In this review, we provide a summary of direct inhibitors targeting NLRP3, elucidating their inhibitory mechanisms, clinical trial phases, and potential applications. Through this discussion, we aim to shed light on the implications of NLRP3 inhibition for the treatment of inflammatory diseases.
Collapse
Affiliation(s)
- Xiu Chen
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China
| | - Pingping Zhang
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China
| | - Yu Zhang
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China
| | - Mengzhu Wei
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China
| | - Tian Tian
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China
| | - Dacheng Zhu
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China
| | - Yanling Guan
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China
| | - Wei Wei
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China.
| | - Yang Ma
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China.
| |
Collapse
|